首页 > 最新文献

Breast Cancer Research and Treatment最新文献

英文 中文
Predicting nodal response to neoadjuvant treatment in breast cancer with core biopsy biomarkers of tumor microenvironment using data mining. 利用数据挖掘的肿瘤微环境核心生物标志物预测乳腺癌新辅助治疗的结节反应。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-04 DOI: 10.1007/s10549-024-07539-9
Nina Pislar, Gorana Gasljevic, Erika Matos, Gasper Pilko, Janez Zgajnar, Andraz Perhavec

Purpose: To generate a model for predicting nodal response to neoadjuvant systemic treatment (NAST) in biopsy-proven node-positive breast cancer patients (cN+) that incorporates tumor microenvironment (TME) characteristics and could be used for planning the axillary surgical staging procedure.

Methods: Clinical and pathologic features were retrospectively collected for 437 patients. Core biopsy (CB) samples were reviewed for stromal content and tumor-infiltrating lymphocytes (TIL). Orange Datamining Toolbox was used for model generation and assessment.

Results: 151/437 (34.6%) patients achieved nodal pCR (ypN0). The following 5 variables were included in the prediction model: ER, Her-2, grade, stroma content and TILs. After stratified tenfold cross-validation, the logistic regression algorithm achieved and area under the ROC curve (AUC) of 0.86 and F1 score of 0.72. Nomogram was used for visualization.

Conclusions: We developed a clinical tool to predict nodal pCR for cN+ patients after NAST that includes biomarkers of TME and achieves an AUC of 0.86 after tenfold cross-validation.

目的:建立一个模型,用于预测活检证实的结节阳性乳腺癌患者(cN+)对新辅助系统治疗(NAST)的结节反应,该模型结合了肿瘤微环境(TME)特征,可用于规划腋窝手术分期程序:方法:回顾性收集了 437 例患者的临床和病理特征。对核心活检(CB)样本的基质含量和肿瘤浸润淋巴细胞(TIL)进行了审查。使用橙色数据挖掘工具箱生成模型并进行评估:151/437(34.6%)例患者达到结节 pCR(ypN0)。预测模型包括以下 5 个变量:ER、Her-2、分级、基质含量和TIL。经过分层十倍交叉验证后,逻辑回归算法的 ROC 曲线下面积(AUC)为 0.86,F1 得分为 0.72。结论:我们开发了一种预测结节的临床工具:我们开发了一种临床工具,用于预测NAST术后cN+患者的结节pCR,其中包括TME的生物标记物,经过十倍交叉验证后,AUC达到0.86。
{"title":"Predicting nodal response to neoadjuvant treatment in breast cancer with core biopsy biomarkers of tumor microenvironment using data mining.","authors":"Nina Pislar, Gorana Gasljevic, Erika Matos, Gasper Pilko, Janez Zgajnar, Andraz Perhavec","doi":"10.1007/s10549-024-07539-9","DOIUrl":"https://doi.org/10.1007/s10549-024-07539-9","url":null,"abstract":"<p><strong>Purpose: </strong>To generate a model for predicting nodal response to neoadjuvant systemic treatment (NAST) in biopsy-proven node-positive breast cancer patients (cN+) that incorporates tumor microenvironment (TME) characteristics and could be used for planning the axillary surgical staging procedure.</p><p><strong>Methods: </strong>Clinical and pathologic features were retrospectively collected for 437 patients. Core biopsy (CB) samples were reviewed for stromal content and tumor-infiltrating lymphocytes (TIL). Orange Datamining Toolbox was used for model generation and assessment.</p><p><strong>Results: </strong>151/437 (34.6%) patients achieved nodal pCR (ypN0). The following 5 variables were included in the prediction model: ER, Her-2, grade, stroma content and TILs. After stratified tenfold cross-validation, the logistic regression algorithm achieved and area under the ROC curve (AUC) of 0.86 and F1 score of 0.72. Nomogram was used for visualization.</p><p><strong>Conclusions: </strong>We developed a clinical tool to predict nodal pCR for cN+ patients after NAST that includes biomarkers of TME and achieves an AUC of 0.86 after tenfold cross-validation.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019. 紫杉类/蒽环类复方制剂降低了不同分子亚型年轻女性的乳腺癌复发率:2011年至2019年台湾地区的真实世界证据。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1007/s10549-024-07527-z
Yu-Ning Chien, Li-Yin Lin, Yi-Chun Lin, Yi-Chen Hsieh, Shih-Hsin Tu, Hung-Yi Chiou

Purpose: Adolescent and young adult (AYA) patients with breast cancer generally have poor prognoses and a higher risk of secondary cancers compared to those at the same cancer stage. Notably, AYA patients in Asia exhibit a higher incidence rate of breast cancer, with Luminal A as the predominant molecular subtype, which contrasts with the trends observed in Western countries. This study aims to compare the efficacy of Taxane/Anthracycline combination-based regimens (TACB) versus Anthracycline-based regimens (AB) in AYA patients with stage I-II breast cancer, focusing on different molecular subtypes.

Methods: This study utilized data from the Taiwan National Health Insurance Research Database (NHIRD) and the Taiwan Cancer Registry (TCR) from 2011 to 2019. The study cohort included patients aged 15 to 39 years who were diagnosed with stage I-II breast cancer and received either TACB or AB regimens. Propensity score matching and Cox proportional hazards regression models were used to calculate the hazard ratios (HR) for recurrence.

Results: The results showed that TACB regimens significantly reduced the risk of recurrence compared to AB regimens across all patients (aHR 0.73, 95% CI 0.55-0.97). Specifically, for low/middle-recurrence risk groups, the aHR was 0.68 (95% CI 0.49-0.96), and for high-recurrence risk groups, it was 0.43 (95% CI 0.21-0.87). The analysis further indicated no significant differences in recurrence risk between AYA and non-AYA patients using TACB regimens.

Conclusion: The TACB regimens showed a more favorable prognosis than AB regimens across all molecular subtypes. Furthermore, TACB regimens not only outperformed AB treatments but also closed the gap in prognostic outcomes between AYA and non-AYA patients. We believe the findings of this study are highly reliable and can provide valuable guidance for physicians in choosing the most appropriate treatment strategies for AYA patients with stage I-II breast cancer.

目的:与处于同一癌症阶段的患者相比,青少年乳腺癌患者的预后一般较差,且继发癌症的风险较高。值得注意的是,亚洲的青少年和青年乳腺癌患者发病率较高,主要分子亚型为Luminal A,这与西方国家观察到的趋势形成鲜明对比。本研究旨在比较以紫杉类/金霉素联合疗法(TACB)为基础的治疗方案与以蒽环类药物为基础的治疗方案(AB)对 I-II 期乳腺癌亚亚裔患者的疗效,重点关注不同的分子亚型:本研究利用了台湾国民健康保险研究数据库(NHIRD)和台湾癌症登记中心(TCR)2011 年至 2019 年的数据。研究队列包括 15 至 39 岁确诊为 I-II 期乳腺癌并接受 TACB 或 AB 方案治疗的患者。研究采用倾向评分匹配和考克斯比例危险回归模型计算复发危险比(HR):结果表明,与 AB 方案相比,TACB 方案能显著降低所有患者的复发风险(aHR 0.73,95% CI 0.55-0.97)。具体而言,低/中复发风险组的 aHR 为 0.68(95% CI 0.49-0.96),高复发风险组为 0.43(95% CI 0.21-0.87)。分析进一步表明,使用TACB疗法的AYA和非AYA患者的复发风险没有明显差异:结论:在所有分子亚型中,TACB 方案的预后均优于 AB 方案。此外,TACB疗法不仅优于AB疗法,还缩小了AYA和非AYA患者在预后结果上的差距。我们相信这项研究的结果非常可靠,能为医生选择最适合 I-II 期乳腺癌 AYA 患者的治疗策略提供有价值的指导。
{"title":"Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019.","authors":"Yu-Ning Chien, Li-Yin Lin, Yi-Chun Lin, Yi-Chen Hsieh, Shih-Hsin Tu, Hung-Yi Chiou","doi":"10.1007/s10549-024-07527-z","DOIUrl":"https://doi.org/10.1007/s10549-024-07527-z","url":null,"abstract":"<p><strong>Purpose: </strong>Adolescent and young adult (AYA) patients with breast cancer generally have poor prognoses and a higher risk of secondary cancers compared to those at the same cancer stage. Notably, AYA patients in Asia exhibit a higher incidence rate of breast cancer, with Luminal A as the predominant molecular subtype, which contrasts with the trends observed in Western countries. This study aims to compare the efficacy of Taxane/Anthracycline combination-based regimens (TACB) versus Anthracycline-based regimens (AB) in AYA patients with stage I-II breast cancer, focusing on different molecular subtypes.</p><p><strong>Methods: </strong>This study utilized data from the Taiwan National Health Insurance Research Database (NHIRD) and the Taiwan Cancer Registry (TCR) from 2011 to 2019. The study cohort included patients aged 15 to 39 years who were diagnosed with stage I-II breast cancer and received either TACB or AB regimens. Propensity score matching and Cox proportional hazards regression models were used to calculate the hazard ratios (HR) for recurrence.</p><p><strong>Results: </strong>The results showed that TACB regimens significantly reduced the risk of recurrence compared to AB regimens across all patients (aHR 0.73, 95% CI 0.55-0.97). Specifically, for low/middle-recurrence risk groups, the aHR was 0.68 (95% CI 0.49-0.96), and for high-recurrence risk groups, it was 0.43 (95% CI 0.21-0.87). The analysis further indicated no significant differences in recurrence risk between AYA and non-AYA patients using TACB regimens.</p><p><strong>Conclusion: </strong>The TACB regimens showed a more favorable prognosis than AB regimens across all molecular subtypes. Furthermore, TACB regimens not only outperformed AB treatments but also closed the gap in prognostic outcomes between AYA and non-AYA patients. We believe the findings of this study are highly reliable and can provide valuable guidance for physicians in choosing the most appropriate treatment strategies for AYA patients with stage I-II breast cancer.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants. BRCA1和BRCA2种系致病变异双杂合子中国乳腺癌患者的特征。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-20 DOI: 10.1007/s10549-024-07409-4
Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie

Purpose: Despite of very rare, breast cancer patients with double heterozygosity (DH) variants in BRCA1 and BRCA2 genes have been identified in other ethnic groups and seem to be associated with distinctive phenotypes. However, little is known about the frequency and clinical characteristics of Chinese breast cancer patients with BRCA1/2 DH variants.

Methods: Four hundred and eleven unrelated patients with BRCA1 or BRCA2 pathogenic variants (PVs) were identified in a large series of unselected breast cancer patients. Another two siblings with metachronous bilateral breast cancer were referred for genetic counseling, after which BRCA1/2 DH variants were detected.

Results: Four unrelated breast cancer patients with BRCA1/2 DH were identified in the cohort of 411 patients with BRCA1 or BRCA2 PVs, the frequency of BRCA1/2 DH was 0.97%. In total, six BRCA1/2 DH patients from five families were found in this study. In two families, the hereditary pattern of DH was speculated to have originated from both sides of the family. BRCA1/2 DH patients were more likely to have a family history of breast cancer than patients with a BRCA1 (100% vs. 29.2%, P = 0.004) or BRCA2 (100% vs. 29.6%, P = 0.004) single PV. BRCA1/2 DH patients were more likely to be triple-negative breast tumors than patients with single BRCA2 PVs (66.7% vs. 14.1%, P = 0.020), which was comparable to the findings in patients with single BRCA1 PVs (66.7% vs. 56.9%, P = 1.00).

Conclusion: Chinese patients with BRCA1/2 DH exhibit a high percentage of family history of breast cancer. The tumor pathological features of BRCA1/2 DH carriers are similar to those of BRCA1 PV carriers.

目的:BRCA1和BRCA2基因双杂合子(DH)变异的乳腺癌患者尽管非常罕见,但已在其他种族群体中发现,并且似乎与独特的表型相关。然而,人们对中国乳腺癌患者中 BRCA1/2 DH 变异的发生频率和临床特征知之甚少:方法:在一大批未经筛选的乳腺癌患者中,发现了 411 名与 BRCA1 或 BRCA2 致病变异体(PVs)无关的患者。另外两名患有同步性双侧乳腺癌的兄弟姐妹被转诊接受遗传咨询,之后检测出了 BRCA1/2 DH 变异:结果:在 411 例 BRCA1 或 BRCA2 PV 患者中,发现了 4 例 BRCA1/2 DH 变异的非亲属乳腺癌患者,BRCA1/2 DH 变异的频率为 0.97%。本研究共发现了来自五个家族的六名 BRCA1/2 DH 患者。在两个家族中,DH 的遗传模式被推测为来自家族双方。与 BRCA1(100% 对 29.2%,P = 0.004)或 BRCA2(100% 对 29.6%,P = 0.004)单一 PV 患者相比,BRCA1/2 DH 患者更有可能有乳腺癌家族史。与单个 BRCA2 PV 患者相比,BRCA1/2 DH 患者更有可能是三阴性乳腺肿瘤(66.7% vs. 14.1%,P = 0.020),这与单个 BRCA1 PV 患者的结果相当(66.7% vs. 56.9%,P = 1.00):结论:中国的 BRCA1/2 DH 患者有较高比例的乳腺癌家族史。结论:BRCA1/2 DH携带者的家族史比例较高,BRCA1/2 DH携带者的肿瘤病理特征与BRCA1 PV携带者相似。
{"title":"Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.","authors":"Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie","doi":"10.1007/s10549-024-07409-4","DOIUrl":"10.1007/s10549-024-07409-4","url":null,"abstract":"<p><strong>Purpose: </strong>Despite of very rare, breast cancer patients with double heterozygosity (DH) variants in BRCA1 and BRCA2 genes have been identified in other ethnic groups and seem to be associated with distinctive phenotypes. However, little is known about the frequency and clinical characteristics of Chinese breast cancer patients with BRCA1/2 DH variants.</p><p><strong>Methods: </strong>Four hundred and eleven unrelated patients with BRCA1 or BRCA2 pathogenic variants (PVs) were identified in a large series of unselected breast cancer patients. Another two siblings with metachronous bilateral breast cancer were referred for genetic counseling, after which BRCA1/2 DH variants were detected.</p><p><strong>Results: </strong>Four unrelated breast cancer patients with BRCA1/2 DH were identified in the cohort of 411 patients with BRCA1 or BRCA2 PVs, the frequency of BRCA1/2 DH was 0.97%. In total, six BRCA1/2 DH patients from five families were found in this study. In two families, the hereditary pattern of DH was speculated to have originated from both sides of the family. BRCA1/2 DH patients were more likely to have a family history of breast cancer than patients with a BRCA1 (100% vs. 29.2%, P = 0.004) or BRCA2 (100% vs. 29.6%, P = 0.004) single PV. BRCA1/2 DH patients were more likely to be triple-negative breast tumors than patients with single BRCA2 PVs (66.7% vs. 14.1%, P = 0.020), which was comparable to the findings in patients with single BRCA1 PVs (66.7% vs. 56.9%, P = 1.00).</p><p><strong>Conclusion: </strong>Chinese patients with BRCA1/2 DH exhibit a high percentage of family history of breast cancer. The tumor pathological features of BRCA1/2 DH carriers are similar to those of BRCA1 PV carriers.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"155-164"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients. 埃及乳腺癌患者基因变异和血清中巨噬细胞迁移抑制因子水平的临床特征。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-25 DOI: 10.1007/s10549-024-07393-9
Mahmoud A Seliem, Ahmed M Mohamadin, Mohamed I Kotb El-Sayed, Yahia Ismail, Ahmed A El-Husseiny

Purpose: Macrophage migration inhibitory factor (MIF) is an integral cytokine for the modulation of both innate and adaptive immunity and is involved in the pathogenesis of various cancers. However, conflicting findings on the relationship between MIF polymorphisms and breast cancer (BC) have been reported in earlier research. We investigated the clinical value of serum MIF levels and the association between MIF rs1049829 and rs755622 variants with their serum levels and propensity to develop BC.

Methods: A total of 133 treatment-naïve Egyptian BC females and 126 apparently healthy controls were matriculated in this case-control study. The serum MIF protein levels were quantified by ELISA, whereas the genotyping was executed utilizing the TaqMan® allelic discrimination assay.

Results: A significant increase in the serum MIF level in BC cases was observed in comparison to control subjects (P < 0.0001), with a diagnostic potential to discriminate BC with 92.5% sensitivity and 73.7% specificity at a cut-off value > 9.47 ng/mL. Besides, a significant difference in serum MIF level was observed in BC cases with progesterone receptor (PR) negativity compared to those with PR positivity (P = 0.046). Moreover, a significant association was depicted between the rs1049829 variant of MIF gene and the protective effect against BC meanwhile the rs755622 variant demonstrated no significant link with BC risk.

Conclusions: This study revealed that serum MIF levels may be regarded as a promising serum tumor marker for BC. Also, the rs1049829 variant of the MIF gene is considered a protective candidate against BC.

目的:巨噬细胞迁移抑制因子(MIF)是调节先天性免疫和适应性免疫不可或缺的细胞因子,并参与多种癌症的发病机制。然而,关于 MIF 多态性与乳腺癌(BC)之间关系的研究结果却相互矛盾。我们研究了血清MIF水平的临床价值,以及MIF rs1049829和rs755622变异与其血清水平和乳腺癌发病倾向之间的关系:这项病例对照研究共纳入了133名未经治疗的埃及BC女性和126名表面健康的对照者。血清 MIF 蛋白水平通过酶联免疫吸附法(ELISA)进行定量,基因分型则通过 TaqMan® 等位基因鉴别检测法进行:结果:与对照组相比,BC 病例的血清 MIF 水平明显升高(P 9.47 ng/mL)。此外,与孕酮受体(PR)阴性的 BC 病例相比,孕酮受体阳性的 BC 病例的血清 MIF 水平有明显差异(P = 0.046)。此外,MIF基因的rs1049829变异与对BC的保护作用有明显关联,而rs755622变异与BC风险无明显联系:结论:本研究表明,血清 MIF 水平可作为 BC 的血清肿瘤标志物。结论:这项研究表明,血清 MIF 水平可被视为 BC 潜在的血清肿瘤标志物,而且 MIF 基因的 rs1049829 变体被认为是 BC 的保护性候选基因。
{"title":"The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients.","authors":"Mahmoud A Seliem, Ahmed M Mohamadin, Mohamed I Kotb El-Sayed, Yahia Ismail, Ahmed A El-Husseiny","doi":"10.1007/s10549-024-07393-9","DOIUrl":"10.1007/s10549-024-07393-9","url":null,"abstract":"<p><strong>Purpose: </strong>Macrophage migration inhibitory factor (MIF) is an integral cytokine for the modulation of both innate and adaptive immunity and is involved in the pathogenesis of various cancers. However, conflicting findings on the relationship between MIF polymorphisms and breast cancer (BC) have been reported in earlier research. We investigated the clinical value of serum MIF levels and the association between MIF rs1049829 and rs755622 variants with their serum levels and propensity to develop BC.</p><p><strong>Methods: </strong>A total of 133 treatment-naïve Egyptian BC females and 126 apparently healthy controls were matriculated in this case-control study. The serum MIF protein levels were quantified by ELISA, whereas the genotyping was executed utilizing the TaqMan® allelic discrimination assay.</p><p><strong>Results: </strong>A significant increase in the serum MIF level in BC cases was observed in comparison to control subjects (P < 0.0001), with a diagnostic potential to discriminate BC with 92.5% sensitivity and 73.7% specificity at a cut-off value > 9.47 ng/mL. Besides, a significant difference in serum MIF level was observed in BC cases with progesterone receptor (PR) negativity compared to those with PR positivity (P = 0.046). Moreover, a significant association was depicted between the rs1049829 variant of MIF gene and the protective effect against BC meanwhile the rs755622 variant demonstrated no significant link with BC risk.</p><p><strong>Conclusions: </strong>This study revealed that serum MIF levels may be regarded as a promising serum tumor marker for BC. Also, the rs1049829 variant of the MIF gene is considered a protective candidate against BC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"57-66"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial. 接受阿那曲唑辅助治疗的乳腺癌患者卵巢功能恢复情况:DATA 3 期试验的最新结果。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-28 DOI: 10.1007/s10549-024-07411-w
Senna W M Lammers, Sandra M E Geurts, Karlijn E P E Hermans, Irene E G van Hellemond, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Aafke H Honkoop, Franchette W P J van den Berkmortel, Wilfred K de Roos, Alexander L T Imholz, Ingeborg J H Vriens, Vivianne C G Tjan-Heijnen

Purpose: Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+) breast cancer (BC) patients with CIOFF. Here, we present the long-term follow-up results.

Methods: Postmenopausal women with HR+ BC who were 45-57 years of age and received chemotherapy were identified from the phase 3 DATA study (NCT00301457) on the extended use of anastrozole. Eligible patients were categorised into two groups: patients with CIOFF and definitely postmenopausal patients. Patients with CIOFF were monitored for OFR. Disease-free survival (DFS), distant recurrence-free survival (DRFS), and overall survival (OS) were compared between patients with OFR and patients without OFR using multivariable Cox regression analyses, including OFR as a time-dependent covariate. BC-specific mortality (BCSM) was compared between groups using the Fine and Gray method.

Results: This study included 656 patients: 395 patients with CIOFF and 261 definitely postmenopausal patients. OFR occurred in 39 (12%) of 329 patients with CIOFF who were monitored for OFR. The median follow-up time was 13.3 years. Patients with OFR experienced a deterioration in DFS (hazard ratio (HR) = 1.54; 95% confidence interval (CI) 0.85-2.81), DRFS (HR = 1.51; 95% CI 0.73-3.11), OS (HR = 1.64; 95% CI 0.75-3.55), and BCSM (subdistribution HR = 1.98; 95% CI 0.84-4.63) when compared with patients without OFR.

Conclusion: In patients with CIOFF, OFR during treatment with anastrozole was associated with a deterioration in BC outcomes. These findings underscore the importance of adequate ovarian function suppression in this subgroup of patients.

目的:化疗引起的卵巢功能衰竭(CIOFF)患者可能会出现卵巢功能恢复(OFR)。早些时候,我们发现阿那曲唑治疗期间的卵巢功能恢复会影响激素受体阳性(HR+)乳腺癌(BC)患者的预后。在此,我们介绍长期随访结果:方法:从关于延长阿那曲唑用药时间的 3 期 DATA 研究(NCT00301457)中筛选出 45-57 岁、接受过化疗的 HR+ BC 绝经后女性患者。符合条件的患者被分为两组:CIOFF 患者和绝经后患者。对CIOFF患者进行OFR监测。使用多变量 Cox 回归分析比较了有 OFR 和无 OFR 患者的无病生存期(DFS)、无远处复发生存期(DRFS)和总生存期(OS),并将 OFR 作为时间依赖性协变量。采用Fine和Gray方法比较了不同组间的BC特异性死亡率(BCSM):本研究共纳入 656 名患者:结果:该研究纳入了 656 名患者:395 名 CIOFF 患者和 261 名绝经后患者。在接受 OFR 监测的 329 名 CIOFF 患者中,有 39 人(12%)发生了 OFR。中位随访时间为 13.3 年。与未发生 OFR 的患者相比,发生 OFR 的患者的 DFS(危险比 (HR) = 1.54;95% 置信区间 (CI) 0.85-2.81)、DRFS(HR = 1.51;95% CI 0.73-3.11)、OS(HR = 1.64;95% CI 0.75-3.55)和 BCSM(亚分布 HR = 1.98;95% CI 0.84-4.63)均有所恶化:结论:在CIOFF患者中,阿那曲唑治疗期间的OFR与BC预后的恶化有关。这些发现强调了充分抑制卵巢功能对这部分患者的重要性。
{"title":"Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.","authors":"Senna W M Lammers, Sandra M E Geurts, Karlijn E P E Hermans, Irene E G van Hellemond, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Aafke H Honkoop, Franchette W P J van den Berkmortel, Wilfred K de Roos, Alexander L T Imholz, Ingeborg J H Vriens, Vivianne C G Tjan-Heijnen","doi":"10.1007/s10549-024-07411-w","DOIUrl":"10.1007/s10549-024-07411-w","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+) breast cancer (BC) patients with CIOFF. Here, we present the long-term follow-up results.</p><p><strong>Methods: </strong>Postmenopausal women with HR+ BC who were 45-57 years of age and received chemotherapy were identified from the phase 3 DATA study (NCT00301457) on the extended use of anastrozole. Eligible patients were categorised into two groups: patients with CIOFF and definitely postmenopausal patients. Patients with CIOFF were monitored for OFR. Disease-free survival (DFS), distant recurrence-free survival (DRFS), and overall survival (OS) were compared between patients with OFR and patients without OFR using multivariable Cox regression analyses, including OFR as a time-dependent covariate. BC-specific mortality (BCSM) was compared between groups using the Fine and Gray method.</p><p><strong>Results: </strong>This study included 656 patients: 395 patients with CIOFF and 261 definitely postmenopausal patients. OFR occurred in 39 (12%) of 329 patients with CIOFF who were monitored for OFR. The median follow-up time was 13.3 years. Patients with OFR experienced a deterioration in DFS (hazard ratio (HR) = 1.54; 95% confidence interval (CI) 0.85-2.81), DRFS (HR = 1.51; 95% CI 0.73-3.11), OS (HR = 1.64; 95% CI 0.75-3.55), and BCSM (subdistribution HR = 1.98; 95% CI 0.84-4.63) when compared with patients without OFR.</p><p><strong>Conclusion: </strong>In patients with CIOFF, OFR during treatment with anastrozole was associated with a deterioration in BC outcomes. These findings underscore the importance of adequate ovarian function suppression in this subgroup of patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"179-192"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis. 将嵌入水凝胶的纳米粒子持续输送塞来昔布至活检腔,防止活检引起的乳腺癌转移。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1007/s10549-024-07410-x
Reese Simmons, Hiroyasu Kameyama, Seiko Kubota, Yunguang Sun, John F Langenheim, Rana Ajeeb, Tristan S Shao, Samantha Ricketts, Anand C Annan, Natalie Stratemeier, Sophie J Williams, John R Clegg, Kar-Ming Fung, Inna Chervoneva, Hallgeir Rui, Takemi Tanaka

Purpose: We have previously reported that protracted Cyclooxygenase-2 (COX-2) activity in bone marrow-derived cells (BMDCs) infiltrating into biopsy wounds adjacent to the biopsy cavity of breast tumors in mice promotes M2-shift of macrophages and pro-metastatic changes in cancer cells, effects which were suppressed by oral administration of COX-2 inhibitors. Thus, local control of COX-2 activity in the biopsy wound may mitigate biopsy-induced pro-metastatic changes.

Methods: A combinatorial delivery system-thermosensitive biodegradable poly(lactic acid) hydrogel (PLA-gel) incorporating celecoxib-encapsulated poly(lactic-co-glycolic acid) nanoparticles (Cx-NP/PLA-gel)-was injected into the biopsy cavity of Py230 murine breast tumors to achieve local control of COX-2 activity in the wound stroma.

Results: A single intra-biopsy cavity injection of PLA-gel loaded with rhodamine-encapsulated nanoparticles (NPs) showed sustained local delivery of rhodamine preferentially to infiltrating BMDCs with minimal to no rhodamine uptake by the reticuloendothelial organs in mice. Moreover, significant reductions in M2-like macrophage density, cancer cell epithelial-to-mesenchymal transition, and blood vessel density were observed in response to a single intra-biopsy cavity injection of Cx-NP/PLA-gel compared to PLA-gel loaded with NPs containing no payload. Accordingly, intra-biopsy cavity injection of Cx-NP/PLA-gel led to significantly fewer metastatic cells in the lungs than control-treated mice.

Conclusion: This study provides evidence for the feasibility of sustained, local delivery of payload preferential to BMDCs in the wound stroma adjacent to the biopsy cavity using a combinatorial delivery system to reduce localized inflammation and effectively mitigate breast cancer cell dissemination.

目的:我们以前曾报道过,浸润到小鼠乳腺肿瘤活检腔附近活检伤口的骨髓衍生细胞(BMDCs)中的环氧化酶-2(COX-2)的长期活性会促进巨噬细胞的M2转移和癌细胞的促转移变化,而口服COX-2抑制剂可抑制这些效应。因此,在活检伤口局部控制 COX-2 的活性可减轻活检引起的促转移变化:方法:将热敏生物可降解聚乳酸水凝胶(PLA-凝胶)与塞来昔布包裹的聚乳酸-甘醇酸纳米颗粒(Cx-NP/PLA-凝胶)组合输送系统注入Py230小鼠乳腺肿瘤的活检腔,以实现对伤口基质中COX-2活性的局部控制:结果:在小鼠活检腔内注射一次装有罗丹明封装纳米颗粒(NPs)的聚乳酸凝胶,结果显示罗丹明可持续地局部输送到浸润的BMDCs,而网状内皮器官对罗丹明的摄取极少甚至没有。此外,与不含有效载荷的 NPs 聚乳酸凝胶相比,在活组织切片腔内注射一次 Cx-NP/PLA 凝胶可明显降低 M2 样巨噬细胞密度、癌细胞上皮细胞向间质细胞的转化以及血管密度。因此,与对照组小鼠相比,活检腔内注射 Cx-NP/PLA 凝胶导致肺部转移细胞明显减少:本研究证明了利用组合递送系统在活检腔附近的伤口基质中持续、局部递送有效载荷优先于BMDCs的可行性,从而减少局部炎症并有效缓解乳腺癌细胞的扩散。
{"title":"Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis.","authors":"Reese Simmons, Hiroyasu Kameyama, Seiko Kubota, Yunguang Sun, John F Langenheim, Rana Ajeeb, Tristan S Shao, Samantha Ricketts, Anand C Annan, Natalie Stratemeier, Sophie J Williams, John R Clegg, Kar-Ming Fung, Inna Chervoneva, Hallgeir Rui, Takemi Tanaka","doi":"10.1007/s10549-024-07410-x","DOIUrl":"10.1007/s10549-024-07410-x","url":null,"abstract":"<p><strong>Purpose: </strong>We have previously reported that protracted Cyclooxygenase-2 (COX-2) activity in bone marrow-derived cells (BMDCs) infiltrating into biopsy wounds adjacent to the biopsy cavity of breast tumors in mice promotes M2-shift of macrophages and pro-metastatic changes in cancer cells, effects which were suppressed by oral administration of COX-2 inhibitors. Thus, local control of COX-2 activity in the biopsy wound may mitigate biopsy-induced pro-metastatic changes.</p><p><strong>Methods: </strong>A combinatorial delivery system-thermosensitive biodegradable poly(lactic acid) hydrogel (PLA-gel) incorporating celecoxib-encapsulated poly(lactic-co-glycolic acid) nanoparticles (Cx-NP/PLA-gel)-was injected into the biopsy cavity of Py230 murine breast tumors to achieve local control of COX-2 activity in the wound stroma.</p><p><strong>Results: </strong>A single intra-biopsy cavity injection of PLA-gel loaded with rhodamine-encapsulated nanoparticles (NPs) showed sustained local delivery of rhodamine preferentially to infiltrating BMDCs with minimal to no rhodamine uptake by the reticuloendothelial organs in mice. Moreover, significant reductions in M2-like macrophage density, cancer cell epithelial-to-mesenchymal transition, and blood vessel density were observed in response to a single intra-biopsy cavity injection of Cx-NP/PLA-gel compared to PLA-gel loaded with NPs containing no payload. Accordingly, intra-biopsy cavity injection of Cx-NP/PLA-gel led to significantly fewer metastatic cells in the lungs than control-treated mice.</p><p><strong>Conclusion: </strong>This study provides evidence for the feasibility of sustained, local delivery of payload preferential to BMDCs in the wound stroma adjacent to the biopsy cavity using a combinatorial delivery system to reduce localized inflammation and effectively mitigate breast cancer cell dissemination.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"165-177"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141537577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three and twelve-month analysis of the PROM-Q study: comparison of patient-reported outcome measures using the BREAST-Q questionnaire in pre- vs. sub-pectoral implant-based immediate breast reconstruction. PROM-Q研究的三个月和十二个月分析:使用BREAST-Q问卷对胸大肌下植入假体前和胸大肌下植入假体后即刻乳房重建的患者报告结果进行比较。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-10 DOI: 10.1007/s10549-024-07416-5
Ritika Rampal, Stacey Jessica Jones, Sue Hartup, Clare Robertson, Wasif Tahir, Sian Louise Jones, Shireen McKenzie, Jessica Anne Savage, Baek Kim

Purpose: Implant-based breast reconstruction (IBR) is being increasingly performed with implant placed above the pectoral muscle (pre-pectoral), instead of below the pectoral muscle (sub-pectoral). Currently, there is a lack of comparative data on clinical and patient-perceived outcomes between pre- vs. sub-pectoral IBR. We investigated whether this difference in surgical approach influenced clinical or patient-perceived outcomes.

Methods: This prospective non-randomised longitudinal cohort study (ClinicalTrials.gov identifier: NCT04842240) recruited patients undergoing immediate IBR at the Leeds Breast Unit (Sep 2019-Sep 2021). Data collection included patient characteristics and post-operative complications. Patient-Reported Outcome Measures were collected using the BREAST-Q questionnaire at baseline, 2 weeks, 3- and 12-months post-surgery.

Results: Seventy-eight patients underwent IBR (46 patients pre-pectoral; 59% vs. 32 patients sub-pectoral; 41%). Similar complication rates were observed (15.2% pre-pectoral vs. 9.4% sub-pectoral; p = 0.44). Overall implant loss rate was 3.8% (6.5% pre-pectoral vs. 0% sub-pectoral; p = 0.13). Respective median Breast-Q scores for pre- and sub-pectoral IBR at 3 months were: breast satisfaction (58 vs. 48; p = 0.01), psychosocial well-being (60 vs. 57; p = 0.9), physical well-being (68 vs. 76; p = 0.53), and Animation Q scores (73 vs. 76; p = 0.45). Respective Breast-Q scores at 12 months were: breast satisfaction (58 vs. 53; p = 0.3), psychosocial well-being (59 vs. 60; p = 0.9), physical well-being (68 vs. 78; p = 0.18), and Animation Q scores (69 vs. 73; p = 0.4).

Conclusions: This study demonstrates equivalent clinical and patient-perceived outcomes between pre- and sub-pectoral IBR. The study findings can be utilised to aid informed decision making regarding either surgical option.

目的:越来越多的植入式乳房重建(IBR)手术将植入物放置在胸大肌上方(胸大肌前),而不是胸大肌下(胸大肌下)。目前,还缺乏胸大肌前与胸大肌下 IBR 的临床和患者感知结果的比较数据。我们研究了手术方法的差异是否会影响临床或患者感知的结果:这项前瞻性非随机纵向队列研究(ClinicalTrials.gov 标识符:NCT04842240)招募了在利兹乳腺科接受即刻 IBR 手术的患者(2019 年 9 月至 2021 年 9 月)。数据收集包括患者特征和术后并发症。使用BREAST-Q问卷收集基线、术后2周、3个月和12个月的患者报告结果:78名患者接受了IBR手术(46名患者为胸骨前手术,占59%;32名患者为胸骨下手术,占41%)。并发症发生率相似(胸骨前 15.2% 对胸骨下 9.4%;P = 0.44)。总体植入物丢失率为 3.8%(胸骨前 6.5% 对胸骨下 0%;p = 0.13)。胸骨前和胸骨下 IBR 在 3 个月时的乳房-Q 评分中位数分别为:乳房满意度(58 分 vs. 48 分;p = 0.01)、社会心理健康(60 分 vs. 57 分;p = 0.9)、身体健康(68 分 vs. 76 分;p = 0.53)和动画 Q 评分(73 分 vs. 76 分;p = 0.45)。12 个月时的乳房-Q 评分分别为:乳房满意度(58 vs. 53;p = 0.3)、社会心理健康(59 vs. 60;p = 0.9)、身体健康(68 vs. 78;p = 0.18)和动画 Q 评分(69 vs. 73;p = 0.4):这项研究表明,口腔前和口腔下 IBR 的临床效果和患者感知效果相当。研究结果可用于帮助患者就两种手术方案做出明智的决策。
{"title":"Three and twelve-month analysis of the PROM-Q study: comparison of patient-reported outcome measures using the BREAST-Q questionnaire in pre- vs. sub-pectoral implant-based immediate breast reconstruction.","authors":"Ritika Rampal, Stacey Jessica Jones, Sue Hartup, Clare Robertson, Wasif Tahir, Sian Louise Jones, Shireen McKenzie, Jessica Anne Savage, Baek Kim","doi":"10.1007/s10549-024-07416-5","DOIUrl":"10.1007/s10549-024-07416-5","url":null,"abstract":"<p><strong>Purpose: </strong>Implant-based breast reconstruction (IBR) is being increasingly performed with implant placed above the pectoral muscle (pre-pectoral), instead of below the pectoral muscle (sub-pectoral). Currently, there is a lack of comparative data on clinical and patient-perceived outcomes between pre- vs. sub-pectoral IBR. We investigated whether this difference in surgical approach influenced clinical or patient-perceived outcomes.</p><p><strong>Methods: </strong>This prospective non-randomised longitudinal cohort study (ClinicalTrials.gov identifier: NCT04842240) recruited patients undergoing immediate IBR at the Leeds Breast Unit (Sep 2019-Sep 2021). Data collection included patient characteristics and post-operative complications. Patient-Reported Outcome Measures were collected using the BREAST-Q questionnaire at baseline, 2 weeks, 3- and 12-months post-surgery.</p><p><strong>Results: </strong>Seventy-eight patients underwent IBR (46 patients pre-pectoral; 59% vs. 32 patients sub-pectoral; 41%). Similar complication rates were observed (15.2% pre-pectoral vs. 9.4% sub-pectoral; p = 0.44). Overall implant loss rate was 3.8% (6.5% pre-pectoral vs. 0% sub-pectoral; p = 0.13). Respective median Breast-Q scores for pre- and sub-pectoral IBR at 3 months were: breast satisfaction (58 vs. 48; p = 0.01), psychosocial well-being (60 vs. 57; p = 0.9), physical well-being (68 vs. 76; p = 0.53), and Animation Q scores (73 vs. 76; p = 0.45). Respective Breast-Q scores at 12 months were: breast satisfaction (58 vs. 53; p = 0.3), psychosocial well-being (59 vs. 60; p = 0.9), physical well-being (68 vs. 78; p = 0.18), and Animation Q scores (69 vs. 73; p = 0.4).</p><p><strong>Conclusions: </strong>This study demonstrates equivalent clinical and patient-perceived outcomes between pre- and sub-pectoral IBR. The study findings can be utilised to aid informed decision making regarding either surgical option.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"275-282"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers. 炎症性乳腺癌的基因组和转录组图谱显示出与非炎症性乳腺癌截然不同的分子特征。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1007/s10549-024-07437-0
Kaiwen Zhou, Mengmeng Zhang, Duanyang Zhai, Zilin Wang, Ting Liu, Yubin Xie, Yawei Shi, Huijuan Shi, Qianjun Chen, Xiaoping Li, Juan Xu, Zhenhai Cai, Yunjian Zhang, Nan Shao, Ying Lin

Purpose: Inflammatory breast cancer (IBC), a rare and highly aggressive form of breast cancer, accounts for 10% of breast cancer-related deaths. Previous omics studies of IBC have focused solely on one of genomics or transcriptomics and did not discover common differences that could distinguish IBC from non-IBC.

Methods: Seventeen IBC patients and five non-IBC patients as well as additional thirty-three Asian breast cancer samples from TCGA-BRCA were included for the study. We performed whole-exon sequencing (WES) to investigate different somatic genomic alterations, copy number variants, and large structural variants between IBC and non-IBC. Bulk RNA sequencing (RNA-seq) was performed to examine the differentially expressed genes, pathway enrichment, and gene fusions. WES and RNA-seq data were further investigated in combination to discover genes that were dysregulated in both genomics and transcriptomics.

Results: Copy number variation analysis identified 10 cytobands that showed higher frequency in IBC. Structural variation analysis showed more frequent deletions in IBC. Pathway enrichment and immune infiltration analysis indicated increased immune activation in IBC samples. Gene fusions including CTSC-RAB38 were found to be more common in IBC. We demonstrated more commonly dysregulated RAS pathway in IBC according to both WES and RNA-seq. Inhibitors targeting RAS signaling and its downstream pathways were predicted to possess promising effects in IBC treatment.

Conclusion: We discovered differences unique in Asian women that could potentially explain IBC etiology and presented RAS signaling pathway as a potential therapeutic target in IBC treatment.

目的:炎症性乳腺癌(IBC)是一种罕见的高侵袭性乳腺癌,占乳腺癌相关死亡人数的 10%。以前对 IBC 的 omics 研究只关注基因组学或转录组学之一,没有发现可以区分 IBC 和非 IBC 的共同差异:研究纳入了 17 例 IBC 患者和 5 例非 IBC 患者,以及来自 TCGA-BRCA 的另外 33 例亚洲乳腺癌样本。我们进行了全外显子测序(WES),以研究 IBC 和非 IBC 之间不同的体细胞基因组改变、拷贝数变异和大结构变异。我们还进行了大量 RNA 测序(RNA-seq),以研究差异表达基因、通路富集和基因融合。进一步结合 WES 和 RNA-seq 数据进行研究,以发现在基因组学和转录组学中出现失调的基因:结果:拷贝数变异分析发现了10个在IBC中频率较高的细胞带。结构变异分析表明,IBC中的基因缺失更为频繁。通路富集和免疫浸润分析表明,IBC样本中的免疫激活增加。基因融合包括 CTSC-RAB38 在 IBC 中更为常见。根据 WES 和 RNA-seq 分析,我们发现在 IBC 中 RAS 通路失调更为常见。针对RAS信号转导及其下游通路的抑制剂预计将在IBC治疗中产生良好的效果:结论:我们发现了亚洲女性的独特差异,这些差异可能解释了 IBC 的病因,并将 RAS 信号通路作为治疗 IBC 的潜在靶点。
{"title":"Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers.","authors":"Kaiwen Zhou, Mengmeng Zhang, Duanyang Zhai, Zilin Wang, Ting Liu, Yubin Xie, Yawei Shi, Huijuan Shi, Qianjun Chen, Xiaoping Li, Juan Xu, Zhenhai Cai, Yunjian Zhang, Nan Shao, Ying Lin","doi":"10.1007/s10549-024-07437-0","DOIUrl":"10.1007/s10549-024-07437-0","url":null,"abstract":"<p><strong>Purpose: </strong>Inflammatory breast cancer (IBC), a rare and highly aggressive form of breast cancer, accounts for 10% of breast cancer-related deaths. Previous omics studies of IBC have focused solely on one of genomics or transcriptomics and did not discover common differences that could distinguish IBC from non-IBC.</p><p><strong>Methods: </strong>Seventeen IBC patients and five non-IBC patients as well as additional thirty-three Asian breast cancer samples from TCGA-BRCA were included for the study. We performed whole-exon sequencing (WES) to investigate different somatic genomic alterations, copy number variants, and large structural variants between IBC and non-IBC. Bulk RNA sequencing (RNA-seq) was performed to examine the differentially expressed genes, pathway enrichment, and gene fusions. WES and RNA-seq data were further investigated in combination to discover genes that were dysregulated in both genomics and transcriptomics.</p><p><strong>Results: </strong>Copy number variation analysis identified 10 cytobands that showed higher frequency in IBC. Structural variation analysis showed more frequent deletions in IBC. Pathway enrichment and immune infiltration analysis indicated increased immune activation in IBC samples. Gene fusions including CTSC-RAB38 were found to be more common in IBC. We demonstrated more commonly dysregulated RAS pathway in IBC according to both WES and RNA-seq. Inhibitors targeting RAS signaling and its downstream pathways were predicted to possess promising effects in IBC treatment.</p><p><strong>Conclusion: </strong>We discovered differences unique in Asian women that could potentially explain IBC etiology and presented RAS signaling pathway as a potential therapeutic target in IBC treatment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"441-459"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141726831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast. 将肿瘤浸润淋巴细胞作为乳腺导管原位癌患者预后生物标志物的评估。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-24 DOI: 10.1007/s10549-024-07466-9
Camila Vitola Pasetto, Fernando Nalesso Aguiar, Marcella Bassan Peixoto, Maíra Teixeira Dória, Bruna Salani Mota, Jonathan Yugo Maesaka, José Roberto Filassi, Edmund Chada Baracat, Rodrigo Gonçalves

Purpose: To assess the association between tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) samples and disease recurrence.

Methods: This retrospective cohort study included women aged 18 years and older who underwent treatment between January 2007 and December 2020. Male patients, individuals diagnosed with invasive or microinvasive disease based on anatomopathological examination of surgical specimens, and those with a personal history of any other cancers were excluded. Additionally, the presence of "touching TILs" (lymphocytes in direct contact with tumor cells) and periductal desmoplasia were evaluated as complementary methods to represent the immunological microenvironment. The primary outcome was relapse-free survival based on TIL quantification adjusted for potential confounders. Pathologists assessed TILs in the sample with the highest tumor representation and quantified them as a percentage. Survival was evaluated using Kaplan‒Meier curves, log-rank tests, and Cox regression models.

Results: A total of 191 patients met the eligibility criteria. The mean follow-up duration was 77.2 months, with a recurrence rate of 9.2%. Patients with TILs ≥ 17% had a greater risk of recurrence (HR 2.97, 95% CI 1.17-7.51; p = 0.02). Additionally, focal necrosis (HR 6.4, 95% CI 1.39-34.71; p = 0.018) or comedonecrosis (HR 4.53, 95% CI 1.34-15.28; p = 0.015) were associated with increased recurrence risk. According to the multivariate model, comedonecrosis and TILs ≥ 17% were significantly associated with recurrence (p = 0.034 and p = 0.035, respectively). Regarding the evaluations of "touching TILs" and periductal desmoplasia, no statistical significance was found when assessing their association with disease recurrence.

Conclusion: In our cohort, a high percentage of TILs (≥ 17%) and the presence of comedonecrosis were independently associated with DCIS recurrence.

目的:评估导管原位癌(DCIS)样本中肿瘤浸润淋巴细胞(TILs)与疾病复发之间的关系:这项回顾性队列研究纳入了 2007 年 1 月至 2020 年 12 月期间接受治疗的 18 岁及以上女性。男性患者、根据手术标本的解剖病理学检查被诊断为浸润性或微小浸润性疾病的患者以及有其他癌症病史的患者均被排除在外。此外,还评估了 "接触性TIL"(与肿瘤细胞直接接触的淋巴细胞)和导管周围脱钙化的存在情况,作为代表免疫微环境的补充方法。主要结果是基于TIL定量的无复发生存期,并对潜在的混杂因素进行了调整。病理学家对肿瘤代表性最高的样本中的TIL进行评估,并将其量化为一个百分比。采用卡普兰-梅耶曲线、对数秩检验和考克斯回归模型对生存率进行评估:共有 191 名患者符合资格标准。平均随访时间为 77.2 个月,复发率为 9.2%。TIL≥17%的患者复发风险更高(HR 2.97,95% CI 1.17-7.51;P = 0.02)。此外,局灶性坏死(HR 6.4,95% CI 1.39-34.71;P = 0.018)或彗星状坏死(HR 4.53,95% CI 1.34-15.28;P = 0.015)与复发风险增加有关。根据多变量模型,合并颌骨坏死和 TIL ≥ 17% 与复发显著相关(分别为 p = 0.034 和 p = 0.035)。关于 "触及TILs "和导管周围脱钙化的评估,在评估其与疾病复发的相关性时未发现统计学意义:结论:在我们的队列中,高比例的TILs(≥ 17%)和存在粉瘤与DCIS复发独立相关。
{"title":"Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.","authors":"Camila Vitola Pasetto, Fernando Nalesso Aguiar, Marcella Bassan Peixoto, Maíra Teixeira Dória, Bruna Salani Mota, Jonathan Yugo Maesaka, José Roberto Filassi, Edmund Chada Baracat, Rodrigo Gonçalves","doi":"10.1007/s10549-024-07466-9","DOIUrl":"10.1007/s10549-024-07466-9","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the association between tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) samples and disease recurrence.</p><p><strong>Methods: </strong>This retrospective cohort study included women aged 18 years and older who underwent treatment between January 2007 and December 2020. Male patients, individuals diagnosed with invasive or microinvasive disease based on anatomopathological examination of surgical specimens, and those with a personal history of any other cancers were excluded. Additionally, the presence of \"touching TILs\" (lymphocytes in direct contact with tumor cells) and periductal desmoplasia were evaluated as complementary methods to represent the immunological microenvironment. The primary outcome was relapse-free survival based on TIL quantification adjusted for potential confounders. Pathologists assessed TILs in the sample with the highest tumor representation and quantified them as a percentage. Survival was evaluated using Kaplan‒Meier curves, log-rank tests, and Cox regression models.</p><p><strong>Results: </strong>A total of 191 patients met the eligibility criteria. The mean follow-up duration was 77.2 months, with a recurrence rate of 9.2%. Patients with TILs ≥ 17% had a greater risk of recurrence (HR 2.97, 95% CI 1.17-7.51; p = 0.02). Additionally, focal necrosis (HR 6.4, 95% CI 1.39-34.71; p = 0.018) or comedonecrosis (HR 4.53, 95% CI 1.34-15.28; p = 0.015) were associated with increased recurrence risk. According to the multivariate model, comedonecrosis and TILs ≥ 17% were significantly associated with recurrence (p = 0.034 and p = 0.035, respectively). Regarding the evaluations of \"touching TILs\" and periductal desmoplasia, no statistical significance was found when assessing their association with disease recurrence.</p><p><strong>Conclusion: </strong>In our cohort, a high percentage of TILs (≥ 17%) and the presence of comedonecrosis were independently associated with DCIS recurrence.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"9-18"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14. 作为早期乳腺癌患者新辅助化疗疗效预测指标的基线肠道微生物群:濑户内乳腺项目-14 的多中心前瞻性队列研究。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-18 DOI: 10.1007/s10549-024-07395-7
Shogo Nakamoto, Yukiko Kajiwara, Kohei Taniguchi, Akira I Hida, Yuichiro Miyoshi, Takanori Kin, Mari Yamamoto, Daisuke Takabatake, Shinichiro Kubo, Hajime Hikino, Yutaka Ogasawara, Masahiko Ikeda, Hiroyoshi Doihara, Tadahiko Shien, Naruto Taira, Takayuki Iwamoto, Shinichi Toyooka

Purpose: Various studies have demonstrated the causal relationship between gut microbiota and efficacy of chemotherapy; however, the impact of gut microbiota on breast cancer has not been fully elucidated. This study aimed to evaluate the associations between the gut microbiota before neoadjuvant chemotherapy and its consequent efficacy in breast cancer.

Methods: This prospective observational study included patients who received neoadjuvant chemotherapy for primary early breast cancer at eight institutions between October 1, 2019, and March 31, 2022. We performed 16S rRNA analysis of fecal samples and α and β diversity analyses of the gut microbiota. The primary endpoint was the association between the gut microbiota and pathological complete response (pCR) to neoadjuvant chemotherapy.

Results: Among the 183 patients, the pCR rate after neoadjuvant chemotherapy was 36.1% in all patients and 12.9% (9/70), 69.5% (41/59), and 29.6% (16/54) in those with the luminal, human epidermal growth factor receptor 2, and triple-negative types, respectively. The α diversity of the gut microbiota did not significantly differ between patients with pCR and those without pCR. Among the gut microbiota, two species (Victivallales, P = 0.001 and Anaerolineales, P = 0.001) were associated with pCR, and one (Gemellales, P = 0.002) was associated with non-pCR.

Conclusion: Three species in the gut microbiota had potential associations with neoadjuvant chemotherapy efficacy, but the diversity of the gut microbiota was not associated with response to chemotherapy. Further research is needed to validate our findings.

目的:多项研究表明,肠道微生物群与化疗疗效之间存在因果关系;然而,肠道微生物群对乳腺癌的影响尚未完全阐明。本研究旨在评估乳腺癌新辅助化疗前肠道微生物群与化疗疗效之间的关系:这项前瞻性观察研究纳入了2019年10月1日至2022年3月31日期间在8家机构接受新辅助化疗的原发性早期乳腺癌患者。我们对粪便样本进行了 16S rRNA 分析,并对肠道微生物群进行了 α 和 β 多样性分析。主要终点是肠道微生物群与新辅助化疗病理完全反应(pCR)之间的关系:在183名患者中,所有患者接受新辅助化疗后的病理完全缓解率为36.1%,管腔型、人表皮生长因子受体2型和三阴型患者的病理完全缓解率分别为12.9%(9/70)、69.5%(41/59)和29.6%(16/54)。肠道微生物群的α多样性在pCR患者和非pCR患者之间没有明显差异。在肠道微生物群中,两个物种(Victivallales,P = 0.001 和 Anaerolineales,P = 0.001)与 pCR 相关,一个物种(Gemellales,P = 0.002)与非 pCR 相关:结论:肠道微生物群中的三个物种与新辅助化疗疗效有潜在关联,但肠道微生物群的多样性与化疗反应无关。需要进一步研究来验证我们的发现。
{"title":"Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14.","authors":"Shogo Nakamoto, Yukiko Kajiwara, Kohei Taniguchi, Akira I Hida, Yuichiro Miyoshi, Takanori Kin, Mari Yamamoto, Daisuke Takabatake, Shinichiro Kubo, Hajime Hikino, Yutaka Ogasawara, Masahiko Ikeda, Hiroyoshi Doihara, Tadahiko Shien, Naruto Taira, Takayuki Iwamoto, Shinichi Toyooka","doi":"10.1007/s10549-024-07395-7","DOIUrl":"10.1007/s10549-024-07395-7","url":null,"abstract":"<p><strong>Purpose: </strong>Various studies have demonstrated the causal relationship between gut microbiota and efficacy of chemotherapy; however, the impact of gut microbiota on breast cancer has not been fully elucidated. This study aimed to evaluate the associations between the gut microbiota before neoadjuvant chemotherapy and its consequent efficacy in breast cancer.</p><p><strong>Methods: </strong>This prospective observational study included patients who received neoadjuvant chemotherapy for primary early breast cancer at eight institutions between October 1, 2019, and March 31, 2022. We performed 16S rRNA analysis of fecal samples and α and β diversity analyses of the gut microbiota. The primary endpoint was the association between the gut microbiota and pathological complete response (pCR) to neoadjuvant chemotherapy.</p><p><strong>Results: </strong>Among the 183 patients, the pCR rate after neoadjuvant chemotherapy was 36.1% in all patients and 12.9% (9/70), 69.5% (41/59), and 29.6% (16/54) in those with the luminal, human epidermal growth factor receptor 2, and triple-negative types, respectively. The α diversity of the gut microbiota did not significantly differ between patients with pCR and those without pCR. Among the gut microbiota, two species (Victivallales, P = 0.001 and Anaerolineales, P = 0.001) were associated with pCR, and one (Gemellales, P = 0.002) was associated with non-pCR.</p><p><strong>Conclusion: </strong>Three species in the gut microbiota had potential associations with neoadjuvant chemotherapy efficacy, but the diversity of the gut microbiota was not associated with response to chemotherapy. Further research is needed to validate our findings.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"67-77"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast Cancer Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1